Tau

News

J&J abandons Alzheimer's antibody in setback for tau

Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.

R&D

Advancements in early detection and innovative therapies tar...

Alzheimer’s disease (AD) robs millions of individuals of their memories, cognitive function, and independence, placing an immense emotional and financial burden on families and healthcare s

News

Lilly's tau drug for Alzheimer's flunks phase 2 test

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

Trial raises hopes for simple Alzheimer’s blood test

Testing a person’s blood for a protein called phosphorylated tau could provide a means of large-scale screening for Alzheimer’s disease (AD), according to a new study.

News

Roche ducks out of AC Immune Alzheimer's antibody alliance

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo

J&J abandons Alzheimer's antibody in setback for tau

Advancements in early detection and innovative therapies tar...

Lilly's tau drug for Alzheimer's flunks phase 2 test

Novo leads $100m financing for Alzheimer's player Asceneuron

Trial raises hopes for simple Alzheimer’s blood test

Roche ducks out of AC Immune Alzheimer's antibody alliance

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Tau

Editor's Picks